AMG 337 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as a selective inhibitor of the MET receptor tyrosine kinase, which plays a crucial role in cell growth, survival, and metastasis. By targeting MET, AMG 337 aims to disrupt signaling pathways that contribute to tumor progression, particularly in cancers where MET amplification or overexpression is observed. Clinical studies have explored its efficacy in treating various solid tumors, including gastric, esophageal, and non-small cell lung cancers. Its development represents a targeted approach to potentially improve outcomes for patients with MET-driven malignancies.